ALFA Finder| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 0.0 | 25.5 | 11.8 |
| Other income | 0.2 | 1.1 | 2.4 |
| Total income | 0.2 | 26.6 | 14.2 |
| Profit before exceptional items & tax | -0.3 | 0.1 | 1.8 |
| Profit before tax | -0.3 | 0.1 | 1.8 |
| Net profit | -0.3 | 0.1 | 1.7 |
| Operating margin | -150.0% | 0.4% | 12.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
BSE results filing, BSE: 543500. Figures extracted from the filing.
Evoq Remedies Ltd: key numbers
- Share price
- ₹1.63
- Market cap
- ₹4.06 Cr
- Revenue (annual)
- ₹25.51 Cr
- Net profit (annual)
- ₹-0.24 Cr
- P/E (TTM)
- -16.9×Sector 54.5×
- Promoter holding
- 0.02%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Evoq Remedies Ltd
All →Evoq Remedies Other Announcement
Evoq Remedies Ltd received approval from the Registrar of Companies to extend the deadline for its 16th Annual General Meeting until 30th October 2026.
Evoq Remedies Insolvency Petition
NCLT admitted CIRP against Evoq Remedies Ltd for a Rs.1.95 Crore operational debt. An IRP has been appointed, and a moratorium is in effect.
- Value
- ₹1.95 Cr
Evoq Remedies Insolvency Petition
An operational creditor has filed an insolvency petition against Evoq Remedies under IBC Section 9. The NCLT admission initiates the CIRP process, posing significant risk for shareholders.
Evoq Remedies Financial Results
Evoq Remedies Limited reported audited financial results for the year ended March 31, 2026. The auditor issued a qualified opinion citing material uncertainty regarding going concern.
Evoq Remedies Financial Results
Evoq Remedies Limited reported annual revenue of ₹26.76 Crore for FY2026. The board also appointed M/s. Jay Pandya & Associates as secretarial auditors for FY2025-26.
- Value
- ₹26.76 Cr
Evoq Remedies Board Meeting Date
Evoq Remedies rescheduled its board meeting from May 27 to May 30, 2026. Directors will consider audited financial results for the fiscal year ended March 31.